|
|
|
|
|
|
|
|
|
|
|
|
|
15.07.26 - 07:06
|
Camurus′ Interim Report Second Quarter 2026 (Cision)
|
|
|
“Record product sales and strong operating performance”
Summary second quarter 2026
April – June
· Total revenues increased 4% (3% at CER[1]) to MSEK 702 (676), (32% increase quarter-on-quarter)
· Product sales increased 13% (11% at CER[1]) to MSEK 528 (470), (24% increase quarter-on-quarter)
· Brixadi[®] royalty revenue increased 42% (37% at CER[1]) to MSEK 127 (89)
· Milestone payments MSEK 46 (115)
· Operating result MSEK 293 (292)
· Cash position at the end of the period BNSEK 4.1 (3.3)
· Complete Response Letter received from the FDA for CAM2029 NDA for...
|
|
|
30.06.26 - 07:06
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund — 30 June 2026 — To ensure that the company can fulfill its commitments under the long-term incentive program for employees of the Camurus group as resolved by the 2026 Annual General Meeting (Performance Share Plan 2026/2029), Camurus issued 570,000 series C shares to Carnegie Investment Bank AB (publ) in June 2026. All series C shares have been repurchased by Camurus and converted into common shares in accordance with a conversion provision in the articles of association.
As a result of the series C share issue with subsequent repurchase and conversion made under Performance Share...
|
|
|
|
|
|
|
11.06.26 - 00:01
|
Camurus provides regulatory update on the US NDA for CAM2029 (Oclaiz™) in acromegaly (Cision)
|
|
|
Lund, Sweden — 10 June 2026 — Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (Oclaiz™), octreotide extended-release injection, for the treatment of patients with acromegaly.
The CRL relates to the observations from the September 2024 cGMP inspection at a third-party manufacturer. FDA has indicated that satisfactory resolution of these observations, which could include a reinspection of the facility, is required before the NDA can be approved. FDA...
|
|
|
02.06.26 - 08:57
|
Eli Lilly: Es geht Schlag auf Schlag – nächster Deal mit Camurus (Der Aktionaer)
|
|
|
Der US-amerikanische Pharma-Riese Eli Lilly bleibt auf Shopping-Tour. Neben zwei Lizenzdeals in Asien konnte das Unternehmen auch eine erweiterte Partnerschaft mit der schwedischen Camurus einfädeln. Für die Skandinavier ist die Erweiterung der Kollaboration vor allem aus finanzieller Sicht von enormer Bedeutung....
|
|
|
|
|
01.06.26 - 17:39
|
Camurus announces expansion of Lilly collaboration (PR Newswire)
|
|
|
LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's......
|
|
|
01.06.26 - 17:36
|
Camurus announces expansion of Lilly collaboration (PR Newswire)
|
|
|
LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's......
|
|
|
|
|
28.05.26 - 19:01
|
Resolutions at the annual general meeting 2026 in Camurus (Cision)
|
|
|
Lund, Sweden — 28 May 2026 — Camurus AB's (CAMX) annual general meeting 2026 was held today, Thursday 28 May, at The Loop in Lund.
The annual general meeting adopted the presented income statements and balance sheets as well as the remuneration report prepared by the Board and granted discharge of liability to Board members and the CEO. In addition, the following main resolutions were passed.
Election of Board members and auditor
Per Olof Wallström, Hege Hellstrøm, Jakob Lindberg, Stefan Persson, Erika Söderberg Johnsson, Fredrik Tiberg, Elisabeth Björk and Robert McQuade were re-...
|
|
|
21.05.26 - 10:01
|
Camurus to present at Jefferies Global Healthcare Conference (Cision)
|
|
|
Lund, Sweden — 21 May 2026 — Camurus (NASDAQ STO: CAMX) will participate in the Jefferies Global Healthcare Conference in New York, 2–4 June, 2026. President and CEO Fredrik Tiberg will present on 3 June at 10.55 pm CET, providing an update on the company's recent developments.
A webcast of the presentation will be available through the following link:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=iX2ZMLifXKSubp3gHo3gjg
For more information
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com (mir@camurus.com)...
|
|
|
|
|
|
|
12.05.26 - 07:00
|
Camurus′ Interim Report January-March 2026 (Cision)
|
|
|
“Q1 performance on track for full-year guidance”
Summary first quarter 2026
January - March
· Total revenues decreased 5% (increased 3% at CER[1]) to SEK 533 (558) million
· Product sales decreased 12% (6% at CER[1]) to SEK 426 (485) million
· Royalties increased 44% (59% at CER[1]) to SEK 106 (74) million
· Operating result decreased 30% (15% at CER[1]) to SEK 168 (239) million
· Profit before tax decreased 28% (14% at CER[1]) to SEK 184 (254) million
· The cash position at the end of the quarter was SEK 3.9 (2.9) billion
· FDA accepted the Oclaiz™ NDA for...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
